[Cancer Research 62, 3347-3350, June 15, 2002]
© 2002 American Association for Cancer Research
Human Cytomegalovirus Infection and Expression in Human Malignant Glioma1
Charles S. Cobbs2,
Lualhati Harkins,
Minu Samanta,
G. Yancey Gillespie,
Suman Bharara,
Peter H. King,
L. Burt Nabors,
C. Glenn Cobbs and
William J. Britt
Surgical Service, Veterans Affairs Medical Center, Birmingham, Alabama [C. S. C., L. H., M. S.]; and Department of Surgery, Division of Neurosurgery [C. S. C., G. Y. G., S. B.], Department of Neurology [P. H. K., L. B. N.], Department of Medicine, Division of Infectious Diseases [C. G. C.], and Department of Pediatrics [W. J. B.], University of Alabama at Birmingham, Birmingham, Alabama 35294
 |
ABSTRACT
|
|---|
Malignant gliomas are the most common primary brain tumors in adults, have no known etiology, and are generally rapidly fatal despite current therapies. Human cytomegalovirus (HCMV) is ß-herpesvirus trophic for glial cells that persistently infects 50–90% of the adult human population. HCMV can be reactivated under conditions of inflammation and immunosuppression, and HCMV gene products can dysregulate multiple cellular pathways involved in oncogenesis. Here we show that a high percentage of malignant gliomas are infected by HCMV and multiple HCMV gene products are expressed in these tumors. These data are the first to show an association between HCMV and malignant gliomas and suggest that HCMV may play an active role in glioma pathogenesis.
|
Introduction
|
|---|
Human herpesviruses are implicated in the pathogenesis of several human malignancies (1)
. HCMV3
is a ß-herpesvirus endemic in the human population that can cause devastating encephalitis in fetuses and immunocompromised adults (2)
. HCMV gene transcription can be activated in astrocytic cells by inflammatory stimuli, and transcriptionally active HCMV can induce malignant transformation and dysregulate key cellular pathways involved in mutagenesis, cell cycle, apoptosis, angiogenesis, cell invasion, and host immune response (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
. Malignant gliomas are thought to be primarily astrocytic in origin and are characterized by increasing degrees of DNA instability, cell proliferation, angiogenesis, and microscopic invasion, with the most malignant form being WHO grade IV astrocytoma (also termed glioblastoma multiforme or GBM; Ref. 14
). We decided to investigate whether HCMV might be involved in glioma pathogenesis because several important cellular pathways in glioma biology that we study also promote, and are promoted by, HCMV gene expression.
|
Materials and Methods
|
|---|
IHC.
Human glioma and meningioma surgical specimens, and Alzheimer’s disease, stroke, encephalitis, cerebritis, and normal brain autopsy specimens were obtained in paraffin blocks (with Institutional Review Board approval) and sectioned (6 µm). Sections were blocked for endogenous peroxidase (3% H2O2, for 12 min) and incubated with Fc receptor blocker (10 min, at 20°C; Innovex Biosciences, Richmond, CA) before the addition of an mAb. We performed IHC using three different three-stage horseradish peroxidase detection systems (BioGenex, San Ramon, CA; Dako, Carpinteria, CA; and Innovex Biosciences) with the following mAbs: anti-IE1–72 (1:25; BioGenex), anti-pp65 (1:30; Novocastra, Newcastle upon Tyne, United Kingdom), anti-p52/76kD (1:30; Novocastra), and anti-CD34 (1:15; BioGenex). Antibody parameters (e.g., postfixation, retrieval, and incubation time) were established for each mAb4
using DAB (Innovex Biosciences) as chromogen. After establishing the presence of a signal, some IE1–72 immunostains were repeated with controls, using catalyzed signal amplification (Dako) to enhance detection.
ISH.
For detection of HCMV nucleic acids, a biotinylated 21-base oligonucleotide (5'-GTGGTGGCGCTGGGGGTGGCG-3') specific for HCMV early gene mRNA and biotinylated positive (specific for polyadenylic mRNA) and negative control (specific for HSV-1/2) probes were obtained (ResGen/Invitrogen, Huntsville, AL). We performed enzyme digestion and nucleic acid denaturation of paraffin sections using a Misha thermocycler (Shandon Lipshaw, Pittsburgh, PA), and slides were hybridized overnight at 37°C in a humidified chamber (methods are detailed in manuscript in preparation).4
Probe was detected using a supersensitive detection system (BioGenex, chromogen NBT). To detect HCMV DNA, we used a digoxigenin-labeled HCMV total genome DNA probe (Zymed Labs, South San Francisco, CA). Positive (specific for endogenous alu DNA sequence) and negative (nonspecific DNA) digoxigenin-labeled control probes were provided by the manufacturer.
Double Labeling of Paraffin Sections for HVMC DNA and GFAP Protein.
ISH for HCMV DNA using the digoxigenin-labeled probe was performed as described. Citra antigen retrieval (BioGenex), endogenous peroxidase block (3% H2O2, 12 min), and Fc receptor block treatments and then anti-GFAP polyclonal antibody were applied (Zymed Labs, 2 h, 20°C). GFAP was detected with a multilink alkaline phosphatase detection system (BioGenex) and NBT chromogen.
Nested PCR and DNA Sequencing.
Glioma DNA was purified from paraffin-embedded surgical specimens of malignant gliomas in accordance with the Institutional Review Board using DNeasy Tissue System (Qiagen, Valencia, CA) according to the manufacturer’s instructions. To avoid contamination, no positive controls were used for PCR, and great care was taken to avoid cross-contamination of paraffin sections during sectioning and DNA preparation. DNA (250 ng) was amplified by nested PCR using internal and external primers specific for HCMV glycoprotein B (UL55) gene as described with minor modifications (15)
. Amplified DNA products from tumors were visualized on agarose gels with ethidium bromide, bands were cut out, and DNA was extracted and analyzed by automated sequencing (ABI Model 377 DNA Sequencer). Confirmation of HCMV sequences was performed using a National Center for Biotechnology Information BLAST search. DNA extractions, PCR amplifications and DNA sequencing were repeated on several tumors in a blinded fashion to confirm these findings.
EM-IHC.
GBM tissues were obtained at surgery and prepared for EM-IHC with anti-pp65 mAb (Novocastra) as described previously (16)
. Secondary antibodies bound to 35-nm gold particles (Electron Microscopy Sciences, Fort Washington, PA) were used for visualization.
|
Results
|
|---|
To determine whether HCMV was present in malignant gliomas, we performed IHC on paraffin sections from 27 malignant glioma surgical specimens obtained from nonimmunocompromised patients using a mAb specific for the HCMV-encoded IE1–72 protein. After optimizing conditions for low levels of expression, we could detect IE1–72 immunoreactivity in 27 of 27 malignant glioma biopsy specimens of various grades (WHO grades II-IV) but not in meningioma biopsy specimens or autopsy specimens from patients with Alzheimer’s disease, stroke, or encephalitis, or from patients without CNS disease (Fig. 1
; Table 1
). In GBMs, IE1–72 immunoreactivity was localized in both the perinuclear cytoplasm and the nucleus of tumor cells. In general, blood vessels within tumors, areas of necrosis, and areas of adjacent normal-appearing brain were minimally or not at all immunoreactive (Fig. 1)
. No immunoreactivity of tumor cells was observed in malignant gliomas when primary antibody was excluded, or when an IgG1 isotype-identical anti-CD34 mAb (specific for endothelial cells) was used. To further assess the extent of HCMV protein expression, we performed IHC on a subset of these glioma specimens using mAbs specific for: (a) HCMV pp65 tegument protein and (b) HCMV Mr 76,000 early protein and Mr 52,000 delayed-early DNA binding protein. Immunoreactivity was detected in at least some tumor cells in all of the glioma specimens that were examined but not in control brain using these mAbs (Fig. 1
; Table 1
).
View larger version (111K):
[in this window]
[in a new window]
|
Fig. 1. Immunohistochemical detection of HCMV in malignant gliomas. Low- (A) and high-power (B) images illustrate IE1–72 immunoreactivity (brown staining) in tumor cells but not areas of vascular proliferation (arrows) or necrosis (small arrow) in a GBM. In another GBM, IE1–72 immunoreactivity is detected in tumor cells surrounding a blood vessel (C) but not in adjacent normal-appearing brain in the same pathological section (D). Serial sections of a third GBM (E–H) illustrate IE1–72 (E), p52/76kD (F), pp65 (G), and CD34 control (H) immunoreactivity [CD34 is detected only in blood vessel endothelial cells (arrows)]. IE1–72 immunoreactivity is observed in a grade II astrocytoma (I) and a grade III oligo-astrocytoma (J). K, IE1–72 is detected in intranuclear inclusions (arrows) and cytoplasm of HCMV-infected lung cells from an AIDS patient (positive control). L, no IE1–72 is detected in normal brain. All of the sections that were counterstained with hematoxylin (blue). Bar: A, 300 µm; B–L, 30 µm.
|
|
View this table:
[in this window]
[in a new window]
|
Table 1 Detection of HCMV proteins in different-grade gliomas, meningiomas, other CNS diseases, and normal brain
Results from IHC with antibodies to four HCMV proteins and CD34 are shown. Anti-IE1-72 antibody was reactive with HCMV-positive control tissues and nonreactive with HSV-1-infected tissue (not shown).
|
|
To confirm that HCMV nucleic acids were present in the same cellular distribution as HCMV proteins in these tumors, we performed ISH to detect HCMV nucleic acids in gliomas and controls using two different HCMV probes and detection systems. Using a biotinylated 21-base oligonucleotide probe specific for HCMV immediate-early gene mRNA, we detected HCMV nucleic acids in glioma specimens but not in controls (Fig. 2, A and D
; Table 2
). No signal was detected in gliomas when a biotinylated 21-base oligonucleotide probe with similar GC content specific for HSV-1 and -2 (HSV-1/2) was used, or when the probe was eliminated from the hybridization reaction (Fig. 2, B and E)
. A positive control probe (specific for polyadenylated mRNA) hybridized with all of the specimens analyzed (gliomas and controls; Fig. 2, C and F
). We repeated these experiments using a digoxigenin-labeled probe specific for DNA from the entire HCMV genome (Fig. 2, G–N
; Table 2
). A nonspecific DNA digoxigenin-labeled probe (Fig. 2, H and K)
, and a digoxigenin-labeled probe specific for endogenous alu DNA sequences (Fig. 2, I, L, and N)
were used as negative and positive controls, respectively. With both of the ISH techniques, we detected HCMV nucleic acids in glioma tumor cells, in endothelial cells in the tumors, and occasionally in tumor-associated vascular smooth muscle cells, but not in normal brain controls (Fig. 2M)
nor in areas of normal brain adjacent to tumor. We confirmed that HCMV DNA was present in cells of glial origin by performing double-labeling experiments using the HCMV DNA ISH probe, followed by IHC with an anti-GFAP antibody (Fig. 2O)
. In glioma specimens that invaded normal brain, we found that HCMV nucleic acids and IE1–72 protein expression were readily detected in areas of tumor but were not detected in areas of normal-appearing brain within the same section (Fig. 1, C and D)
. To confirm the specificity of our HCMV oligonucleotide ISH probe and anti-IE1–72 mAb in gliomas, we infected human U251 GBM cells in culture with HCMV strain AD169 (multiplicity of infection, 5–10) and performed ISH and IHC. By both IHC and ISH, we could readily detect IE1–72 immunoreactivity and HCMV nucleic acid hybridization, respectively, in AD169-infected U251 cells but not in uninfected U251 cells (not shown).
View larger version (119K):
[in this window]
[in a new window]
|
Fig. 2. ISH for HCMV nucleic acids using two different probes in a grade II astrocytoma (A–C, G–I) and a GBM (D–F, J–L). A, HCMV nucleic acids are detected with a biotinylated 21-base oligonucleotide probe specific for HCMV immediate-early gene mRNA in a grade II astrocytoma (A) and GBM (D); purple, chromogen NBT). B and E, negative controls; no probe added (identical result was obtained when a biotinylated probe specific for HSV-1/2 was used). C and F, poly(thymidylic acid)-positive control probe hybridizes with RNA in both tumors. Hybridization with HCMV nucleic acids is observed in the same grade II astrocytoma (G) and GBM (J) with a digoxigenin-labeled DNA probe specific for the entire HCMV genome (brown chromogen, DAB). A digoxigenin-labeled negative control probe does not hybridize with nucleic acids in these tumors (H and K). A positive control digoxigenin-labeled probe specific for alu-DNA repeats hybridizes with nucleic acids in tumors (I, L) and normal brain control (N). No hybridization is detected in normal brain with the digoxigenin-labeled probe specific for HCMV DNA (M). O, Double-labeled cells: ISH with HCMV genomic DNA probe (chromogen DAB), and IHC with anti-GFAP antibody (chromogen NBT) illustrates positive brown nuclei surrounded by dark blue GFAP-positive cytoplasm in a GBM. Sections G–N are counterstained with hematoxylin (blue). Bars: A–N, 100 µm; O, 40 µm.
|
|
View this table:
[in this window]
[in a new window]
|
Table 2 Detection of HCMV nucleic acids in different-grade gliomas, meningiomas, other CNS diseases, and normal brain
ISH results with two different HCMV probes are shown. HCMV nucleic acids were detected in glioma specimens but not in normal brain nor in other CNS diseases. HSV-1/2 probe was negative in tumor and normal brain and positive in HSV-1-infected tissue (not shown).
|
|
To further analyze the HCMV present in these glioma specimens, we selected cases that were positive for HCMV by ISH and extracted DNA from the original paraffin blocks for use in PCR reactions to amplify HCMV nucleic acids. Using DNA from paraffin sections of nine different malignant gliomas, we performed nested PCR for a polymorphic region of the HCMV glycoprotein B (UL55) gene. We amplified UL55 in seven of nine of these paraffin-derived GBM DNA samples with nested PCR. A 141-bp PCR product was cut from the agarose gels of these PCR reactions, the DNA was extracted, and direct DNA sequencing was performed. Of these seven tumors from which UL55 DNA sequencing was performed, two tumors had a gB-1 (Towne prototype) genotype, three tumors had a gB-2 (AD-169 prototype) genotype, and two tumors had a variation of either genotype (data not shown).
To determine whether HCMV viral particles could be identified in human gliomas, two GBMs obtained at the time of surgery were analyzed by immunogold EM-IHC. We used an anti-pp65 mAb labeled with a secondary antibody bound to gold particles. In both tumors, rare electron-dense particles labeled with gold were identified that were morphologically consistent with HCMV virions (Fig. 3)
.
View larger version (101K):
[in this window]
[in a new window]
|
Fig. 3. Immunogold electron micrograph of pp65 mAb reactivity in an infiltrative human GBM tumor specimen. A, scattered electron-dense particles, ranging from 120 to 250 nm, are observed in a cell surrounded by myelinated axons (arrows) at x8,000 (bar, 2 µm). B, x40,000 view of boxed area from A shows electron-dense particles morphologically consistent with HCMV particles (arrows) in the cytoplasm of the cell (bar, 400 nm). Inset in B, is x70,000 view of boxed area showing a 35-nm immunogold pp65-labeled particle of  140-nm diameter.
|
|
|
Discussion
|
|---|
These data are the first to show that HCMV nucleic acids and proteins are present in a high percentage of low- and high-grade malignant gliomas, and that the expression of early and delayed HCMV gene products occurs in these tumors. Although these data do not establish a causal role for HCMV in glioma pathogenesis, a wealth of existing data indicates that HCMV could facilitate glioma progression. Human herpesviruses are implicated in the pathogenesis of several human cancers, although the exact mechanisms of oncogenesis are incompletely understood. In EBV- and human herpesvirus 8-related malignancies, viral reactivation is believed to occur after years of latency and to lead to malignancy (1)
. Factors such as inflammatory cytokine activation of latently infected cells and inborn and/or acquired host immunological characteristics are thought to be important in determining which individuals with these viral infections succumb to malignancies. We hypothesize that HCMV infection of glioma cells may be attributable to reactivation of an underlying persistent astrocytic or endothelial cell infection, or to de novo infection of glial cells that have acquired defects in cell cycle control mechanisms. HCMV gene expression in a glial cell that does not lead to cell cycle arrest or apoptosis might promote clonal expansion without producing a productive or cytopathic viral infection. Indeed, existing data indicate that long-term passage of HCMV in malignant glioma cells can result in the occurrence of variant strains with minimal cytopathic effect, and that HCMV can be reactivated in latently infected glioma cells when the cells are exposed to inflammatory stimuli or superinfected with other HCMV strains (17
, 18)
. Sustained expression of specific HCMV gene products in such a setting might promote the overall glioma phenotype because HCMV encodes for gene products that can dysregulate cellular pathways involved in mutagenesis, apoptosis, cell cycle, angiogenesis, cell invasion, and host antitumor immune response (5, 6, 7, 8, 9, 10, 11, 12, 13)
. HCMV gene products can also transactivate other oncogenic viruses that are associated with malignant gliomas such as JC virus (19
, 20)
, and may synergize with such viruses to promote oncogenesis. Thus, the potential role or roles of HCMV in glioma pathogenesis may not conform to existing paradigms in viral oncogenesis, and further research based on these findings may lead to a better understanding of the biology of this malignancy and reveal novel treatment or prevention strategies.
|
ACKNOWLEDGMENTS
|
|---|
We thank Dr. George M. Shaw for critical review of the manuscript and Dr. Ivan Mikolaenko for technical assistance.
|
FOOTNOTES
|
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 C. S. C. is supported by a Merit Review Grant for Cancer Research from the Veterans Administration. 
2 To whom requests for reprints should be addressed, at University of Alabama-Birmingham, Division of Neurosurgery, MEB 519, 1813 Sixth Avenue South, Birmingham, AL 35294. Phone: (205) 934-2918; Fax: (205) 975-5791; E-mail: cscobbs{at}uabmc.edu
3 The abbreviations used are: HCMV, human cytomegalovirus; GBM, glioblastoma multiforme; IHC, immunohistochemistry; mAb, monoclonal antibody; EM, electron microscopy; DAB, 3,3'-diaminobenzidine; HSV, herpes simplex virus; IE1, immediate-early 1; ISH, in situ hybridization; GFAP, glial fibrillary acidic protein; CNS, central nervous system; NBT, nitro blue tetrazolium.
4 L. Harkins and C. S. Cobbs. Immunohistochemical and in situhybridization detection of human cytomegalovirus in human malignant gliomas, manuscript in preparation.
Received 4/ 3/02.
Accepted 4/25/02.
|
REFERENCES
|
|---|
-
Howley P. M., Ganem D., Kieff E. DNA viruses De Vita V. T., Jr. Hellman S. Rosenberg S. A. eds. . Cancer: Principles and Practice of Oncology, 168-173, Lippincott Williams and Wilkins Philadelphia 2001.
-
Britt W. J., Alford C. A. Cytomegalovirus Fields B. N. Knipe D. M. Howley P. M. eds. . Fields Virology, Ed. 3 2493-2523, Raven Press New York 1996.
-
Fritschy J. M., Brandner S., Aguzzi A., Koedood M., Luscher B., Mitchell P. J. Brain cell type specificity and gliosis-induced activation of the human cytomegalovirus immediate-early promoter in transgenic mice. J. Neurosci., 16: 2275-2282, 1996.[Abstract/Free Full Text]
-
Wolff D., Sinzger C., Drescher P., Jahn G., Plachter B. Reduced levels of IE2 gene expression and shutdown of early and late viral genes during latent infection of the glioblastoma cell line U138-MG with selectable recombinants of human cytomegalovirus. Virology, 204: 101-113, 1994.[Medline]
-
Doniger J., Muralidhar S., Rosenthal L. J. Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate. Clin. Microbiol. Rev., 12: 367-382, 1999.[Abstract/Free Full Text]
-
Shen Y., Zhu H., Shenk T. Human cytomegalovirus IE1 and IE2 proteins are mutagenic and mediate "hit-and-run" oncogenic transformation in cooperation with the adenovirus E1A proteins. Proc. Natl. Acad. Sci. USA, 94: 3341-3345, 1997.[Abstract/Free Full Text]
-
Zhu H., Shen Y., Shenk T. Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J. Virol., 69: 7960-7970, 1995.[Abstract]
-
Loenen W. A., Bruggeman C. A., Wiertz E. J. Immune evasion by human cytomegalovirus: lessons in immunology and cell biology. Semin. Immunol., 13: 41-49, 2001.[Medline]
-
Salvant B. S., Fortunato E. A., Spector D. H. Cell cycle dysregulation by human cytomegalovirus: influence of the cell cycle phase at the time of infection and effects on cyclin transcription. J. Virol., 72: 3729-3741, 1998.[Abstract/Free Full Text]
-
Lokensgard J. R., Cheeran M. C., Gekker G., Hu S., Chao C. C., Peterson P. K. Human cytomegalovirus replication and modulation of apoptosis in astrocytes. J. Hum. Virol., 2: 91-101, 1999.[Medline]
-
Cinatl J., Jr., Kotchetkov R., Scholz M., Cinatl J., Vogel J. U., Driever P. H., Doerr H. W. Human cytomegalovirus infection decreases expression of thrombospondin- 1 independent of the tumor suppressor protein p53. Am. J. Pathol., 155: 285-292, 1999.[Abstract/Free Full Text]
-
Speir E., Modali R., Huang E. S., Leon M. B., Shawl F., Finkel T., Epstein S. E. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science (Wash. DC), 265: 391-394, 1994.[Abstract/Free Full Text]
-
Scholz M., Scholz M., Blaheta R. A., Wittig B., Cinatl J., Vogel J. U., Doerr H. W., Cinatl J., Jr. Cytomegalovirus-infected neuroblastoma cells exhibit augmented invasiveness mediated by ß1
5 integrin (VLA-5). Tissue Antigens, 55: 412-421, 2000.[Medline]
-
Prados M. D., Levin V. Biology and treatment of malignant glioma. Semin. Oncol., 27: 1-10, 2000.
-
Kuhn J. E., Wendland T., Eggers H. J., Lorentzen E., Wieland U., Eing B., Kiessling M., Gass P. Quantitation of human cytomegalovirus genomes in the brain of AIDS patients. J. Med. Virol., 47: 70-82, 1995.[Medline]
-
Turbat-Herrera E. A., Harkins L., Herrera G. A. Immunoelectron microscopy in diagnostic pathology Rose N. R. de Macario E. C. Folds J. D. Lane H. C. Nakamura R. M. eds. . Manual of Clinical Laboratory Immunology, 431-443, ASM Press Washington DC 1997.
-
Poland S. D., Costello P., Dekaban G. A., Rice G. P. Cytomegalovirus in the brain: in vitro infection of human brain-derived cells. J. Infect. Dis., 162: 1252-1262, 1990.[Medline]
-
Ogura T., Tanaka J., Kamiya S., Sato H., Ogura H., Hatano M. Human cytomegalovirus persistent infection in a human central nervous system cell line: production of a variant virus with different growth characteristics. J. Gen. Virol., 67: 2605-2616, 1986.[Abstract/Free Full Text]
-
Winklhofer K. F., Albrecht I., Wegner M., Heilbronn R. Human cytomegalovirus immediate-early gene 2 expression leads to JCV replication in nonpermissive cells via transcriptional activation of JCV T antigen. Virology, 275: 323-334, 2000.[Medline]
-
Del Valle L., Gordon J., Assimakopoulou M., Enam S., Geddes J. F., Varakis J. N., Katsetos C. D., Croul S., Khalili K. Detection of JC virus DNA sequences and expression of the viral regulatory protein T-antigen in tumors of the central nervous system. Cancer Res., 61: 4287-4293, 2001.[Abstract/Free Full Text]
This article has been cited by other articles:
|
|
|
|
 
M. N. Prichard, E. Sztul, S. L. Daily, A. L. Perry, S. L. Frederick, R. B. Gill, C. B. Hartline, D. N. Streblow, S. M. Varnum, R. D. Smith, et al.
Human Cytomegalovirus UL97 Kinase Activity Is Required for the Hyperphosphorylation of Retinoblastoma Protein and Inhibits the Formation of Nuclear Aggresomes
J. Virol.,
May 15, 2008;
82(10):
5054 - 5067.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Cobbs, L. Soroceanu, S. Denham, W. Zhang, and M. H. Kraus
Modulation of Oncogenic Phenotype in Human Glioma Cells by Cytomegalovirus IE1-Mediated Mitogenicity
Cancer Res.,
February 1, 2008;
68(3):
724 - 730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Mitchell, W. Xie, R. Schmittling, C. Learn, A. Friedman, R. E. McLendon, and J. H. Sampson
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma
Neuro-oncol,
February 1, 2008;
10(1):
10 - 18.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Nogalski, J. P. Podduturi, I. B. DeMeritt, L. E. Milford, and A. D. Yurochko
The Human Cytomegalovirus Virion Possesses an Activated Casein Kinase II That Allows for the Rapid Phosphorylation of the Inhibitor of NF-{kappa}B, I{kappa}B{alpha}
J. Virol.,
May 15, 2007;
81(10):
5305 - 5314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. N. Streblow, K. W. R. van Cleef, C. N. Kreklywich, C. Meyer, P. Smith, V. Defilippis, F. Grey, K. Fruh, R. Searles, C. Bruggeman, et al.
Rat Cytomegalovirus Gene Expression in Cardiac Allograft Recipients Is Tissue Specific and Does Not Parallel the Profiles Detected In Vitro
J. Virol.,
April 15, 2007;
81(8):
3816 - 3826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Luo, K. Rosenke, K. Czornak, and E. A. Fortunato
Human Cytomegalovirus Disrupts both Ataxia Telangiectasia Mutated Protein (ATM)- and ATM-Rad3-Related Kinase-Mediated DNA Damage Responses during Lytic Infection
J. Virol.,
February 15, 2007;
81(4):
1934 - 1950.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Altieri, F. Castro, J. L. Bermejo, and K. Hemminki
Association between number of siblings and nervous system tumors suggests an infectious etiology
Neurology,
December 12, 2006;
67(11):
1979 - 1983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. C. Casavant, M. H. Luo, K. Rosenke, T. Winegardner, A. Zurawska, and E. A. Fortunato
Potential Role for p53 in the Permissive Life Cycle of Human Cytomegalovirus.
J. Virol.,
September 1, 2006;
80(17):
8390 - 8401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Maussang, D. Verzijl, M. van Walsum, R. Leurs, J. Holl, O. Pleskoff, D. Michel, G. A. M. S. van Dongen, and M. J. Smit
Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis
PNAS,
August 29, 2006;
103(35):
13068 - 13073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Sanchez and D. H. Spector
Cyclin-Dependent Kinase Activity Is Required for Efficient Expression and Posttranslational Modification of Human Cytomegalovirus Proteins and for Production of Extracellular Particles.
J. Virol.,
June 1, 2006;
80(12):
5886 - 5896.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Erlach, V. Bohm, C. K. Seckert, M. J. Reddehase, and J. Podlech
Lymphoma cell apoptosis in the liver induced by distant murine cytomegalovirus infection.
J. Virol.,
May 1, 2006;
80(10):
4801 - 4819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. English, R. S. Chumanov, S. H. Gellman, and T. Compton
Rational Development of beta-Peptide Inhibitors of Human Cytomegalovirus Entry
J. Biol. Chem.,
February 3, 2006;
281(5):
2661 - 2667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Melnychuk, P. Smith, C. N. Kreklywich, F. Ruchti, J. Vomaske, L. Hall, L. Loh, J. A. Nelson, S. L. Orloff, and D. N. Streblow
Mouse Cytomegalovirus M33 Is Necessary and Sufficient in Virus-Induced Vascular Smooth Muscle Cell Migration
J. Virol.,
August 15, 2005;
79(16):
10788 - 10795.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tang, W. Shao, M. T. Dorak, Y. Li, R. Miike, E. Lobashevsky, J. K. Wiencke, M. Wrensch, R. A. Kaslow, and C. S. Cobbs
Positive and Negative Associations of Human Leukocyte Antigen Variants with the Onset and Prognosis of Adult Glioblastoma Multiforme
Cancer Epidemiol. Biomarkers Prev.,
August 1, 2005;
14(8):
2040 - 2044.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Terrasson, S. Allart, H. Martin, J. Lule, H. Haddada, D. Caput, and C. Davrinche
p73-Dependent Apoptosis through Death Receptor: Impairment by Human Cytomegalovirus Infection
Cancer Res.,
April 1, 2005;
65(7):
2787 - 2794.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. B. DeMeritt, L. E. Milford, and A. D. Yurochko
Activation of the NF-{kappa}B Pathway in Human Cytomegalovirus-Infected Cells Is Necessary for Efficient Transactivation of the Major Immediate-Early Promoter
J. Virol.,
May 1, 2004;
78(9):
4498 - 4507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. N. Streblow, J. Vomaske, P. Smith, R. Melnychuk, L. Hall, D. Pancheva, M. Smit, P. Casarosa, D. D. Schlaepfer, and J. A. Nelson
Human Cytomegalovirus Chemokine Receptor US28-induced Smooth Muscle Cell Migration Is Mediated by Focal Adhesion Kinase and Src
J. Biol. Chem.,
December 12, 2003;
278(50):
50456 - 50465.
[Abstract]
[Full Text]
[PDF]
|
|
|
Top
ABSTRACT
Introduction
